Correction to: Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials | Zendy

AI Assistant Blog Pricing

Correction to: Kidney Function After Initiation and Discontinuation of Empagliflozin in Patients With Heart Failure With and Without Type 2 Diabetes: Insights From the EMPERIAL Trials

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.